RT Journal Article
SR Electronic
T1 Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.26.20239368
DO 10.1101/2020.11.26.20239368
A1 Huisman, Jana S.
A1 Scire, Jérémie
A1 Angst, Daniel C.
A1 Li, Jinzhou
A1 Neher, Richard A.
A1 Maathuis, Marloes H.
A1 Bonhoeffer, Sebastian
A1 Stadler, Tanja
YR 2021
UL http://medrxiv.org/content/early/2021/06/24/2020.11.26.20239368.abstract
AB The effective reproductive number Re is a key indicator of the growth of an epidemic. Since the start of the SARS-CoV-2 pandemic, many methods and online dashboards have sprung up to monitor this number through time. However, these methods are not always thoroughly tested, correctly placed in time, or are overly confident during high incidence periods. Here, we present a method for near real time estimation of Re, applied to epidemic data from 170 countries. We thoroughly evaluate the method on simulated data, and present an intuitive web interface for interactive data exploration. We show that in the majority of countries the estimated Re dropped below 1 only after the introduction of major non-pharmaceutical interventions. For Europe the implementation of non-pharmaceutical interventions was broadly associated with reductions in the estimated Re. Globally though, relaxing non-pharmaceutical interventions had more varied effects on subsequent Re estimates. Our framework is useful to inform governments and the general public on the status of the epidemic in their country, and is used as the official source of Re estimates in Switzerland. It further allows detailed comparison between countries and in relation to covariates such as implemented public health policies, mobility, behaviour, or weather data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss National Science Foundation (SNSF) through grant number 31CA30_196267 (to TS), 200021_172603 (to MHM), 310030B_176401 (to SB), and NRP72 grant 407240-167121 (to SB and TS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics commitee was involved as no clinical trial data was used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source code of the pipeline is available at https://github.com/covid-19-Re/shiny-dailyRe. The resulting estimates (data) are available at: https://github.com/covid-19-Re/dailyRe-Data. The code necessary to reproduce the figures in the paper is at: https://github.com/covid-19- Re/paper-code. The underlying linelist data for Switzerland was provided to us by the Federal Office of Public Health, and is not publicly available due to privacy concerns. For all other countries, the incidence data can be downloaded from public sources using the pipeline in the repository mentioned above. https://github.com/covid-19-Re/shiny-dailyRe https://github.com/covid-19-Re/dailyRe-Data https://github.com/covid-19-Re/paper-code